A single-arm phase 2 trial investigating ensartinib in second-line ALK+ NSCLC demonstrated an ORR of 52% (48), which led to its approval by the National Medical Products Administration (NMPA) of China. The gene discussed is ALK; the disease is non-small cell lung carcinoma.